Cargando…

Eculizumab‐related drug reaction in a patient with neuromyelitis optica

Eculizumab is approved for treatment of antibody positive neuromyelitis optica, myasthenia gravis, and hematologic disorders like paroxysmal nocturnal hemoglobinuria. Drug rash has not yet been reported as a side effect of eculizumab. We report a case of a cutaneous drug reaction soon after introduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Rishi, Romo, Moises, Nelson, Flavia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909165/
https://www.ncbi.nlm.nih.gov/pubmed/36789316
http://dx.doi.org/10.1002/ccr3.6835